Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Oncology Associates PC — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Nebraska: - NHO Revive Research Institute, LLC — Lincoln, Nebraska
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Nebraska: - GSK Investigational Site — Omaha, Nebraska
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- Fred and Pamela Buffett Cancer Center - Kearney — Kearney, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Nebraska Hematology and Oncology — Lincoln, Nebraska
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Oncology Associates PC — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC - MECC — Omaha, Nebraska
- Nebraska Methodist Hospital — Omaha, Nebraska
- Oncology Associates PC — Omaha, Nebraska
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Nebraska: - Children's Hospital and Medical Center of Omaha — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Nebraska: - University of Nebraska Medical Center Buffet Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Nebraska: - Exelixis Clinical Site #2 — Omaha, Nebraska
- Exelixis Clinical Site #5 — Omaha, Nebraska
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Nebraska: - Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Nebraska: - Massive Bio SYNERGY-AI site — Omaha, Nebraska
NA Recruiting Industry
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…
Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska